Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
US |
|
OPTIMIZERx Corp
NASDAQ:OPRX
|
US |
|
O
|
Orell Fuessli AG
XBER:OFH
|
CH |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
FR |
|
Abb Ltd
OTC:ABLZF
|
CH |
|
D
|
Debock Industries Ltd
NSE:DIL
|
IN |
|
ESR-REIT
OTC:CGIUF
|
SG |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
US |
|
M&G PLC
OTC:MGPFY
|
UK |
|
CAE Inc
TSX:CAE
|
CA |
|
N
|
Northern Trust Corp
DUS:NT4
|
US |
|
Westpac Banking Corp
ASX:WBC
|
AU |
|
A
|
Absa Group Ltd
JSE:ABG
|
ZA |
|
K
|
Kawasaki Heavy Industries Ltd
DUS:KHE
|
JP |
|
B
|
Beyond Securities PCL
SET:BYD
|
TH |
|
Volta Metals Ltd
OTC:VOLMF
|
CA |
Wall St Price Targets
BMRN Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for BMRN is 92.68 USD with a low forecast of 55.55 USD and a high forecast of 126 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BMRN's stock price target?
Price Target
92.68
USD
According to Wall Street analysts, the average 1-year price target for BMRN is 92.68 USD with a low forecast of 55.55 USD and a high forecast of 126 USD.
What is the Revenue forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 8 years is 14%.
What is the Net Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Net Income over the next 8 years is 23%.
